← Back to patent-cliff list
Imetelstat
Tier C — Watch / tradeImetelstat
Geron Co
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：TERT
Brand：RYTELO
Indications (approved)：Myelodysplastic syndrome, Anaemia
Regional status
US
Approved
2024-06-06
EU
Approved
2025-03-07
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Imetelstat?
Approved indications include: Myelodysplastic syndrome, Anaemia.
When does the Imetelstat patent expire?
No public expiry year is available for Imetelstat yet; this page updates once verified.
How do I get a quote for Imetelstat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27